T. Rowe Price Associates’s Immunome IMNM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $27.7M | Sell |
2,982,080
-87,527
| -3% | -$814K | ﹤0.01% | 886 |
|
|
2025
Q1 | $20.7M | Buy |
3,069,607
+786,853
| +34% | +$5.3M | ﹤0.01% | 945 |
|
|
2024
Q4 | $24.2M | Buy |
2,282,754
+246,447
| +12% | +$2.62M | ﹤0.01% | 944 |
|
|
2024
Q3 | $29.8M | Buy |
2,036,307
+15,188
| +0.8% | +$222K | ﹤0.01% | 895 |
|
|
2024
Q2 | $24.5M | Sell |
2,021,119
-224,554
| -10% | -$2.72M | ﹤0.01% | 905 |
|
|
2024
Q1 | $55.4M | Buy |
2,245,673
+1,194,451
| +114% | +$29.5M | 0.01% | 706 |
|
|
2023
Q4 | $11.2M | Buy |
1,051,222
+877,592
| +505% | +$9.39M | ﹤0.01% | 1071 |
|
|
2023
Q3 | $1.45M | Buy |
+173,630
| New | +$1.45M | ﹤0.01% | 1615 |
|
|
2021
Q4 | – | Sell |
-10,800
| Closed | -$263K | – | 3009 |
|
|
2021
Q3 | $263K | Buy |
+10,800
| New | +$263K | ﹤0.01% | 2617 |
|